Liraglutide decreases postprandial fibroblast growth factor 19 and glucagon-like peptide 2, and increases postprandial cholecystokinin in individuals with obesity

A. Bronden, H. H. Nerild, C. C. Nexoe-Larsen, P. H. Hellmann, M. Baekdal, I. M. Gether, M. P. Gillum, Bolette Hartmann, L. B. Knudsen, L. V. Jacobsen, J. F. Rehfeld, J. J. Holst, T. Vilsboll, D. P. Sonne, F. K. Knop

Original languageEnglish
Publication dateSept 2021
Number of pages1
Publication statusPublished - Sept 2021

Cite this